A/N: I own nothing. Not even a clean bill of health.

Number: PRF-002

Designation: 'Ivysaur'

Class: Euclid

Containment Procedures: PRF-002 is to be kept in a chamber no less than 5m x 5m x 3m, with ventilation readily available. However, under no circumstances should this ventilation system be connected to the rest of Site-[REDACTED]'s airflow systems. (See Incident Log 001-A.) Water should always be readily available for PRF-002, and food consisting of mostly leafy plants, with mealworms interspersed, should be delivered thrice daily. All personnel entering the containment unit should wear breathing filtration masks and are to report to the onsite shower facility immediately after leaving the chamber. Any instance of PRF-002-1 being created while personnel are within the chamber requires that the afflicted personnel report to the onsite medical facilities as soon as possible.

Description: PRF-002 appears to be a medium-sized, turquoise-coloured creature, approximately 1m in height, weighing roughly 13kg. The creature takes the shape of a quadrupedal reptile, which some researchers have seen similarities to dinosaurs in. (Side note: Dr. E has suggested that this family of creatures have more in common with toads than dinosaurs. After observing the movements of the creatures, E4 Command is inclined to agree.) The large green bulb that was present in its time as PRF-001 has undergone a metamorphosis, becoming a large flowering plant, though it should be noted that the petals of the flower are not fully opened in this stage. The effects of attempting to remove this plant are identical to the effects noted in PRF-001's file. As of -/-/-, all testing on PRF-002's bulb is to be halted, by order of E4 Command. PRF-002 will occasionally produce clouds of spores, like those produced by its previous form, collectively designated PRF-002-1. As before, these spores appear relatively harmless to humans in small doses, though their effects on smaller mammals is increased. (See Testing Log 002-A.) The effect of these spores appears to have become more pronounced. While PRF-002 does not appear to age in any way, upon the death of PRF-003, the bulb on its back will begin to undergo metamorphosis, and PRF-002 will transform into an identical copy of PRF-003. At this point, PRF-002 is to be re-designated as PRF-003 and moved to its new containment chamber.

Testing Log 002-A: Tests were carried out to obtain information about the effects of PRF-002-1.

Test 002-1:

Subject: Common rat, no genetic abnormalities, average health.

Procedure: Subject was exposed to approximately 10mg of PRF-002-1 and observed.

Result: Subject appeared to experience temporary paralysis, lasting for approximately 9.7 minutes. Subject remained incapable of opening its right eyelid for the remainder of its life and experienced drastically shortened lifespan.

Test 002-2:

Subject: Common rat, no genetic abnormalities, average health.

Procedure: Subject was exposed to approximately 50mg of PRF-002-1 and observed.

Result: Subject experienced severe paralysis across its entire body and died during experiment at an unknown time. Scientists assigned to the specimen indicated mild electric shocks being received from the specimen's fur, uncertain as to cause.

Test 002-3:

Subject: Common rat, no genetic abnormalities, average health.

Procedure: Subject was connected to an EEG and a heart rate monitor, before being exposed to approximately 50mg of PRF-002-1 and observed.

Results: Identical to Test 002-2, however due to the monitoring equipment, TOD was determined to be approximately 4.2 minutes into the subject's paralysis.

Test 002-4:

Subject: D-287, male, Caucasian, 28 years of age. No genetic anomalies, average health.

Procedure: Subject connected to an EEG and heart monitor, before being exposed to approximately 10mg of PRF-002-1 and observed.

Results: A few seconds into the test, subject reported severe itching coming from his left pectoral, which was later determined to have received the highest concentration of PRF-002-1. 3 minutes into the test, subject became unresponsive. 2 hours later, subject began responding again, and revealed similar symptoms as in Test 001-6. Test concluded.

Test 002-5:

Subject: D-287, male, Caucasian, 28 years of age. No genetic anomalies, average health.

Procedure: Subject connected to an EEG and heart monitor, before being exposed to approximately 50mg of PRF-002-1 and observed.

Results: Subject exhibited a severe skin rash, comparable to that associated with severe hypoallergenic reactions, and remained in a state of paralysis for approximately 46 hours. No other effects noted. (Side note: Subject appeared to develop asthma, however circumstances prevented testing to determine the cause of the condition.)

Test 002-6:

Subject: D-287, male, Caucasian, 28 years of age. No genetic anomalies, average health, mild asthma (see previous test report).

Procedure: Subject connected to an EEG and heart monitor, before being exposed to approximately 100mg of PRF-002-1 and observed.

Results: Subject exhibited extraordinarily severe skin rash within seconds of exposure, before immediately entering a paralysed state. Subject expired 3 minutes into the test. Subject made only one vocalization in this time, immediately after exposure. Analysis of the data indicates a high probability the subject was attempting to request help from staff on-site.

Test 002-7:

Subject: PRF-150.

Notes: Given results of Test 002-6, E4 Command felt it necessary to determine if PRF-002-1 can at least contain PRF-150.

Procedure: Subject exposed to approximately 100mg of PRF-002-1.

Results: Despite having been exposed to well over the maximum non-lethal dosage for humans, PRF-150 did not show any signs of harm. No skin rash was observed to form however the paralysis effect did still occur. PRF-150 remained paralysed for 27.6 hours, well below the hypothesized recovery time for the dosage received. Request was submitted, and granted, to use PRF-002-1 as an additional containment measure for PRF-150. No lasting effects noted.